Clinical trials: Lung Non-Small Cell Carcinoma
Metastatic Solid Cancers, Colorectal Cancer
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses.
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06253520
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Lung Cancer Squamous Cell, Lung Cancer Stage IV
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with stage IV squamous non-small cell lung cancer who had not received systemic chemotherapy.
- Conditions
- Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody, Chemotherapy Effect
- Trial name
- NCT03668496
- Testing
- SHR-1210
- Where
- 53 sites in China
- Volunteers
- 390 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
- Trial name
- NCT07164170
- Testing
- ABSK043 in combination with Glecirasib
- Where
- 17 sites in China
- Volunteers
- 86 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Non Small Cell Lung Carcinoma
Non-small Cell Lung Cancer Study US75 (Z-PACT)
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer.
- Trial name
- ZPACT (NCT00086268)
- Testing
- zoledronic acid, Taxotere, Carboplatin
- Where
- 80 sites in United States
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2.
- Trial name
- NCT00034268
- Testing
- LY900003
- Where
- 105 sites in United States, Argentina and 19 more
- Sponsor
- Eli Lilly and Company
Non-small-cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers
Lung cancer patients have a poor prognosis and only around 20 % is alive after 5 years. However, for advanced non-small cell lung cancer immunotherapy has become a cornerstone of treatment.
- Conditions
- Non-small-cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
- Trial name
- LimBio (NCT03658460)
- Testing
- DNA sequencing
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Aalborg University Hospital
Non-small-cell Lung Cancer
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00364780
- Testing
- XL647
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Kadmon Corporation, LLC
Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic
Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)
Metformin is thought to activate AMP-activated protein kinase (AMPK), a major sensor of cellular energy levels and a key enzyme limiting cellular growth during times of cellular stress.
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
- Trial name
- METRO (NCT02019979)
- Testing
- metformin, carbohydrate restricted diet
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Medical Center
Carcinoma, Non-Small-Cell Lung
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed).
- Trial name
- NCT03952403
- Testing
- HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin
- Where
- China
- Volunteers
- 643 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Cancer, Lung Cancer
Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients
The goal of this research study is to look at how long individuals who have been treated for early stage NSCLC or HNSCC live without developing lung cancer.
- Trial name
- NCT00352391
- Testing
- Assessments
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Psychosocial
Effects of Cancer Symptoms on Caregivers
The primary objectives are to: 1.1 identify and compare the experiences of minority and nonminority caregivers, including the prevalence and severity of physical (fatigue, sleep disturbance) and psychologic (depression, anxiety…
- Trial name
- NCT00351988
- Testing
- Phenomenological Interviews, Quantitative Interviews
- Where
- 4 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281970
- Testing
- cisplatin, docetaxel, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Small Cell Lung Cancer
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
- Trial name
- NCT03878537
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Scripps Translational Science Institute
Lung Cancer
Study of Tumor Samples From Patients With Lung Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900328
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
This is an open label phase 2 study to evaluate the combination of Vigil™ and nivolumab in advanced or metastatic NSCLC that is progressive on or after one prior platinum-based systemic therapy.
- Conditions
- Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02639234
- Testing
- Vigil™, Nivolumab
- Where
- 3 sites in United States
- Sponsor
- Gradalis, Inc.
Non-small Cell Lung Cancer
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
- Trial name
- NCT03758287
- Testing
- CT053PTSA, Gefitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Lung Cancer
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.
- Trial name
- NCT00144053
- Testing
- Cisplatin+Vindesine+MMC/ concurrent radiation, Irinotecan+Carboplatin/concurrent radiation, Paclitaxel+Carboplatin/concurrent radiation
- Volunteers
- 450 people
- Sponsor
- West Japan Thoracic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.